De Boer

HOVER Wins a 2023 Pro Tool Innovation Award In Technology

Retrieved on: 
Thursday, September 14, 2023
Insurance, PTIA, Network, Army Network Enterprise Technology Command, Customer, SAN, De Boer, Safety, Tutoring, Sales

SAN FRANCISCO, Sept. 14, 2023 /PRNewswire-PRWeb/ -- HOVER, the technology company building the largest, most comprehensive spatial data model used to connect the homeowner and construction professional to transform the home improvement process, has received the prestigious 2023 Pro Tool Innovation Award within the Networking and Technology category. In its eleventh year, the Pro Tool Innovation Awards brought to light an impressive assortment of pioneering power tools, hand tools, technology solutions, and tool accessories.

Key Points: 
  • HOVER has received the prestigious 2023 Pro Tool Innovation Award within the Networking and Technology category.
  • SAN FRANCISCO, Sept. 14, 2023 /PRNewswire-PRWeb/ -- HOVER, the technology company building the largest, most comprehensive spatial data model used to connect the homeowner and construction professional to transform the home improvement process, has received the prestigious 2023 Pro Tool Innovation Award within the Networking and Technology category.
  • In its eleventh year, the Pro Tool Innovation Awards brought to light an impressive assortment of pioneering power tools, hand tools, technology solutions, and tool accessories.
  • The 2023 Pro Tool Innovation Award winners are a testament to the companies and products that propel the construction, landscaping, automotive, and manufacturing industries forward.

SubMFG Installs Epson Dye-Sublimation and DTG Printers for Increased Business Productivity and Efficiency

Retrieved on: 
Wednesday, April 19, 2023
Epson, History, DTG, LOS, De Boer, OEM, 3D printing, Textile printing

LOS ALAMITOS, Calif., April 19, 2023 /PRNewswire/ -- As a high-demand, technology-focused cut-and-sew warehouse, SubMFG was looking to improve their in-house technology for a more efficient process. After attending industry trade shows to learn about the latest technology, SubMFG selected and installed the Epson SureColor® F10070 and SureColor F10070H production dye-sublimation printers and multiple SureColor F3070 direct-to-garment (DTG) printers as turnkey solutions to produce their signature apparel offerings. As a result, SubMFG has experienced increased business productivity and output efficiency, further increasing their in-house capabilities and output capacity. 

Key Points: 
  • As a result, SubMFG has experienced increased business productivity and output efficiency, further increasing their in-house capabilities and output capacity.
  • Epson customer SubMFG has increased business productivity with their dye-sublimation and direct-to-garment solutions.
  • Since installing the SureColor dye-sublimation printers, the SubMFG team has benefited from the production-focused features designed for round-the-clock productivity.
  • Since installing the SureColor F10070 and F10070H, SubMFG has added DTG printing to their in-house capabilities, installing multiple SureColor F3070 DTG printers.

TOTAL DIVERSITY CLINICAL TRIAL MANAGEMENT EXPERIENCING RAPID GROWTH

Retrieved on: 
Thursday, April 13, 2023
Communication, Crystal, Business development, Growth, De Boer, Social media, Senior, Strategic management, African Americans, Marketing, Management

DALLAS, April 13, 2023 /PRNewswire/ -- TOTAL Diversity Clinical Trial Management (TOTAL), a full-service diversity organization announces the expansion of the business development and marketing teams to meet increased demands for services.

Key Points: 
  • DALLAS, April 13, 2023 /PRNewswire/ -- TOTAL Diversity Clinical Trial Management (TOTAL), a full-service diversity organization announces the expansion of the business development and marketing teams to meet increased demands for services.
  • In addition to the expansion of Geurts' role, TOTAL announces Gabrielle DeBoer's role as Vice President, Business Development.
  • DeBoer has more than 30 years of experience in sales, with the last 20 of those years in the clinical research industry.
  • Jeremy is a passionate advocate for diversity and inclusion and is an active member of Minorities in Clinical Research, whose mission is to advocate for diversity and inclusion in the healthcare industry.

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Retrieved on: 
Thursday, August 11, 2022
People, U.S. Securities and Exchange Commission, GLOBE, LCA, Clinical trial, Prevalence, Security (finance), Research, Eli Lilly, Patient, RNA, PIN, CEP290, ADAR, Leber congenital amaurosis, Hearing loss, Intravitreal injection, Illuminate, Lists of diseases, Disease, Liver, Union, Risk, CNS, Retinitis pigmentosa, Technology, Life, Marketing, Western world, Partnership, Safety, Ophthalmology, Nasdaq, Axiom Space, RNA transfection, De Boer, Wind, Intellectual property, Forward-looking statement, European Medicines Agency, Therapy, COVID-19, Eon, Program, Severe cognitive impairment, Nervous system, Mutation, Annual report, PRIME, MAA, FDA, ProQR, IP, Usher syndrome, Company, Sirius, Eye, EMA, Video game console, Vaccine, Pharmaceutical industry, USH2A, Inosine, Guanosine, Adenosine

Further to the announcement in April 2022 on the Companys strategy, going forward, ProQR will focus exclusively on accelerating the development of its Axiomer RNA-editing platform technology.

Key Points: 
  • Further to the announcement in April 2022 on the Companys strategy, going forward, ProQR will focus exclusively on accelerating the development of its Axiomer RNA-editing platform technology.
  • The Company will provide further updates on the Axiomer strategy, including announcing its internal development targets in late 2022/early 2023.
  • As we prioritize the development of our Axiomer RNA editing platform technology, we believe partnering our ophthalmology assets is the best strategy to drive these programs forward to patients, said Daniel A. de Boer, Chief Executive Officer of ProQR Therapeutics.
  • ProQR is pioneering a next-generation RNA technology called Axiomer, which could potentially yield a new class of medicines for genetic diseases.

Think tank continues to help drive nation's green agenda

Retrieved on: 
Tuesday, June 14, 2022
Leadership, ClientEarth, Multilateralism, Time, Program, Palm oil, Transport, Developed country, Horse, Policy, Environment, Government, Environmental planning, Mineral, De Boer, Chinese Academy of Governance, Lees, Development, Growth, Club, Attitude, Employment, Climate, Learning, History, Climate change, Carbon, GDP, Renewable energy, Toy, Management, Tourism, Drug, Public relations, Medical device, Medicine, Agriculture

He served three five-year terms as a member of the high-level think tank that reports to the government.

Key Points: 
  • He served three five-year terms as a member of the high-level think tank that reports to the government.
  • Three decades have passed since then, and the country has not only seen its economy boom, but also made significant environmental progress.
  • "Developed countries don't have these kinds of things because they think they know it all.
  • "It's not really happening yet, but I think it willmaybe in another five to 10 years," he said.

New Partners Join Heidrick & Struggles in Europe

Retrieved on: 
Friday, June 10, 2022
Leadership, Heidrick, Consultant, Time, De Boer, North West Regional Leaders Board, Marketing, Organization, Female, Heidrick & Struggles, Management

Silvia Eggenweiler joined Heidrick & Struggles as a partner in the Frankfurt office, bringing more than 20 years of experience.

Key Points: 
  • Silvia Eggenweiler joined Heidrick & Struggles as a partner in the Frankfurt office, bringing more than 20 years of experience.
  • Aleid de Boer joined Heidrick & Struggles as a partner in the Amsterdam office, bringing more than 20 years of experience.
  • Eggenweiler and de Boer represent two strategic female additions to the ranks of European partners at Heidrick & Struggles since the start of 2021.
  • Heidrick & Struggles pioneered the profession of executive search more than 65 years ago.

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Retrieved on: 
Wednesday, June 1, 2022
Axiom Space, Company, Adenosine deaminase, Doctor of Philosophy, COVID-19, Supervisory board, University of Nijmegen (1655–80), U.S. Securities and Exchange Commission, Alnylam Pharmaceuticals, Intellectual property, Cancer, Forward-looking statement, CEO, MyTomorrows, Mass meeting, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, General counsel, Corporation, University, RNA, Security (finance), ProQR, Shareholder, Patient, Chief financial officer, Lawyer, GE Capital, AGM, Lists of diseases, Janssen Vaccines, Mutation, Leadership, Research, Annual report, Nasdaq, Therapy, GLOBE, ADAR, Risk, Corporate development, De Boer, Safety, Management, Pharmaceutical industry, Renewable energy

ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.

Key Points: 
  • ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.
  • Mr. Beukema is also nominated to join the Management Board, subject to approval by shareholders at the AGM.
  • Most recently, he has been General Counsel & Chief Corporate Development at Frame Cancer Therapeutics.
  • He is the scientific co-founder of ProQR and previously served as ProQRs Chief Innovation Officer from 2014 to 2022.